In DESTINY-Lung02 trial Presented by Dr. Koichi Goto, Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg and 6.4 mg/kg demonstrated clinically meaningful activity in pts with previously treated HER2-mutant metastatic NSCLC. In this phase II trial, the cORR was 53.8% and 42.9% in pts receiving T-DXd 5.4 or 6.4 mg/kg, respectively. Based on this trial, the FDA has recently approved T-DXd (5.4 mg/kg IV every 3 weeks) in this setting.
.png)